Akero Therapeutics, Inc. (AKRO)
$54.65+0.00%Close
BUYBULL · day 38
Key stats
- Market cap
- $4.5B
- Beta
- -0.40
- P/E (TTM)
- -29.54
- 1W
- +0.29%
- 1M
- +1.13%
- vs SPY 1W
- +0.43%
- vs SPY 1M
- -1.38%
Industry peers
FMP comparable companies · ranked by market cap
- KYMRSELLKymera Therapeutics, Inc.$9.2BBEARQ 25$112.08-4.82%
- CRNXBUYCrinetics Pharmaceuticals, Inc.$9.0BBULLQ 26$84.95+0.00%
- PRAXSELLPraxis Precision Medicines, Inc.$7.0BCRISISQ 11$251.38-3.20%
- ACLXArcellx, Inc.$6.7B$115.07
- CNTACentessa Pharmaceuticals plc$6.3B$40.50
- IMVTSELLImmunovant, Inc.$6.1BCRISISQ 25$29.48-2.61%
- ACADSELLAcadia Pharmaceuticals Inc.$3.3BCRISISQ 17$19.41-4.07%
- VKTXSELLViking Therapeutics, Inc.$3.3BCRISISQ 21$28.34-5.96%
- SLNOSoleno Therapeutics, Inc.$2.8B$53.01
- NAMSSELLNewAmsterdam Pharma Company N.V.$2.5BCRISISQ 24$21.25-4.99%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on AKRO?
- LOPJLB’s latest quantitative signal on Akero Therapeutics, Inc. (AKRO) is BUY in a BULL regime. Signals are updated daily.
- What market regime is AKRO in?
- Akero Therapeutics, Inc. (AKRO) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Akero Therapeutics, Inc. (AKRO) do?
- Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of …